India Pharma - IPM Growth Normalises In July, With Reduced Covid-19 Cases: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Indian pharma market growth was 13.7% YoY in July 2021 versus 14.1% YoY in June 2021.
Anti-Infectives/analgesics/respiratory exhibited a growth of 30%/24.1%/22.8% YoY.
Respiratory sales were steady YoY in July 2021 (23.3% YoY growth in June 2021) as well.
On a moving annual total basis, industry growth stood at 12.8% YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.